Alx oncology announces first patient dosed in aspen-04, a phase 2 study of alx148 in combination with keytruda® (pembrolizumab) and chemotherapy for the treatment of patients with advanced head and neck squamous cell carcinoma

The second of two distinct randomized phase 2 studies in collaboration with merck has been initiated the second of two distinct randomized phase 2 studies in collaboration with merck has been initiated

ALXO Ratings Summary

ALXO Quant Ranking